SNAP25
SNAP25
Main page
1783430

SNAP25

logo
Community Hub0 subscribers
Read side by side
SNAP25
View on Wikipedia
from Wikipedia
SNAP25
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesSNAP25, CMS18, RIC-4, RIC4, SEC9, SNAP, SNAP-25, bA416N4.2, dJ1068F16.2, SUP, synaptosome associated protein 25kDa, synaptosome associated protein 25
External IDsOMIM: 600322; MGI: 98331; HomoloGene: 13311; GeneCards: SNAP25; OMA:SNAP25 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6616

20614

Ensembl

ENSG00000132639

ENSMUSG00000027273

UniProt

P60880

P60879

RefSeq (mRNA)

NM_011428
NM_001291056
NM_001355254
NM_001355255

RefSeq (protein)

NP_001277985
NP_035558
NP_001342183
NP_001342184

Location (UCSC)Chr 20: 10.17 – 10.31 MbChr 2: 136.56 – 136.62 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Synaptosomal-Associated Protein, 25kDa (SNAP-25) is a Target Soluble NSF (N-ethylmaleimide-sensitive factor) Attachment Protein Receptor (t-SNARE) protein encoded by the SNAP25 gene found on chromosome 20p12.2 in humans.[5][6] SNAP-25 is a component of the trans-SNARE complex, which accounts for membrane fusion specificity and directly executes fusion by forming a tight complex that brings the synaptic vesicle and plasma membranes together.[7]

Structure and function

[edit]
Molecular machinery driving exocytosis in neuromediator release. The core SNARE complex is formed by four α-helices contributed by synaptobrevin, syntaxin and SNAP-25. Synaptotagmin serves as a Ca2+ sensor and intimately regulates SNARE zipping.[8]

SNAP-25, a Q-SNARE protein, is anchored to the cytosolic face of membranes via palmitoyl side chains covalently bound to cysteine amino acid residues in the central linker domain of the molecule. This means that SNAP-25 does not contain a trans-membrane domain.[9]

SNAP-25 has been identified to contribute two[10] α-helices to the SNARE complex, a four-α-helix domain complex.[11] The SNARE complex participates in vesicle fusion, which involves the docking, priming and merging of a vesicle with the cell membrane to initiate an exocytotic event. Synaptobrevin, a protein that is a part of the vesicle-associated membrane protein (VAMP) family, and syntaxin-1 also help form the SNARE complex by each contributing a single α-helix. SNAP-25 assembles with synaptobrevin and syntaxin-1, and the selective binding of these proteins enables vesicle docking and fusion to occur at active zones on the plasma membrane.[12] The energy needed for fusion to occur, results from the assembly of the SNARE proteins along with additional Sec1/Munc18-like (SM) proteins.[13]

To form the SNARE complex, synaptobrevin, syntaxin-1, and SNAP-25 associate and begin to wrap around each other to form a coiled coil quaternary structure. The α-helices of both synaptobrevin and syntaxin-1 bind to those of SNAP-25. Synaptobrevin binds the α-helix near the C-terminus of SNAP-25, while syntaxin-1 binds the α-helix near the N-terminus.[9] Dissociation of the SNARE complex is driven by ATPase N-ethylmaleimide-sensitive fusion (NSF) protein.[13]

SNAP-25 inhibits presynaptic P-, Q-, and L-type voltage-gated calcium channels[14] and interacts with the synaptotagmin C2B domain in a Ca2+-independent fashion.[15] In glutamatergic synapses, SNAP-25 decreases the Ca2+ responsiveness, while it is normally absent in GABAergic synapses.[16]

Two isoforms (mRNA splice variants) of SNAP-25 exist, which are SNAP-25a and SNAP-25b. The two isoforms differ by nine amino acid residues, including a re-localization of one of the four palmitoylated cysteine residues involved in membrane attachment.[17] The major characteristics of these two forms are outlined in the table below.

SNAP25a SNAP25b
Structure N-terminal α-helix

Random coil linker region with four cysteines clustered towards the center

C-terminal α-helix

N-terminal α-helix

Random coil linker region with four cysteines clustered towards the C-terminus

C-terminal α-helix

Expression Major SNAP-25 isoform in embryos and developing neural tissue

Minimal expression in adult tissue except in pituitary and adrenal gland tissues

Minimal expression during development, major isoform in adult neural tissue[18]
Localization Diffuse Localized to terminals and varicosities[18]

SNAP-25 not only plays a role in synaptogenesis and the exocytotic release of neurotransmitters, but it also affects spine morphogenesis and density, post synaptic receptor trafficking and neuronal plasticity. Other non-neuronal processes such as metabolism can also be affected by SNAP-25 protein expression.[19][20]

Clinical significance

[edit]

Developmental and epileptic encephalopathies (DEEs)

[edit]

Individuals harboring pathogenic heterozygous de novo missense or loss-of-function variants in SNAP-25 often present with an early-onset developmental and epileptic encephalopathy. The core symptoms comprise intellectual disability ranging between mild to profound and early-onset seizures mostly occurring before the age of two years. Further recurrent symptoms include movement disorders, cerebral visual impairment, and brain atrophy.[21] Electrophysiological studies identified aberrant spontaneous neurotransmission as causative and suggest that structurally clustered pathogenic variants lead to similar synaptic phenotypes.[22]

Attention Deficit Hyperactivity Disorder (ADHD)

[edit]

Consistent with the regulation of synaptic Ca2+ responsiveness, heterozygous deletion of the SNAP-25 gene in mice results in a hyperactive phenotype similar to attention deficit hyperactivity disorder (ADHD). In heterozygous mice, a decrease in hyperactivity is observed with dextroamphetamine (or Dexedrine), an active ingredient in the ADHD drug Adderall. Homozygous deletions of the SNAP-25 gene are lethal. An additional study indicated that incorporation of a SNAP-25 transgene back into the heterozygous SNAP-25 mutant mouse can rescue normal activity levels similar to wildtype mice. This suggests that low protein levels of SNAP-25 can be a cause of hyper-kinetic behavior.[23] Subsequent studies have suggested that at least some of the SNAP-25 gene mutations in humans might predispose to ADHD.[24][25] Identification of polymorphisms in the 3' untranslated region of the SNAP-25 gene was established in linkage studies with families that had been pre-diagnosed ADHD.[26]

Schizophrenia

[edit]

Studies in the post mortem brains of patients with Schizophrenia have shown that altered protein levels of SNAP-25 are specific to regions of the brain. Reduced SNAP-25 protein expression has been observed in the hippocampus as well as an area of the frontal lobe known as Broadman's area 10 whereas SNAP-25 expression has increased in both the cingulate cortex and prefrontal lobe of Broadman's area 9. The varying levels of SNAP-25 protein found in different areas of the brain have been thought to contribute to the conflicting psychological behaviors (depressive vs. hyperactive) expressed in some Schizophrenic patients.[27][28][29][30]

The blind-drunk (Bdr) mouse model which has a point mutations in the SNAP-25b protein has provided a complex phenotype involving behaviors such as an abnormal circadian rhythm,[31] uncoordinated gait, and disinterest in new objects/toys.[32] Another mouse model generated from Cre-LoxP recombination, showed that conditional knockout (cKO) of the SNAP-25 gene in the forebrain, showed inactive SNAP-25 gene expression in glutamatergic neurons. However, significant glutamate levels were found in the cortex of these cKO mice.[33] These mice also exhibited deficient social skills, impaired learning and memory, enhanced kinesthetic activity, a reduced startle response, impaired self-care, nursing ability and nest-building skills. Antipsychotic drugs such as Clozapine and Riluzole have been shown to significantly reduce the schizophrenic phenotype expressed in SNAP-25 cKO mice.[33]

Alzheimer's disease

[edit]

Individuals with Alzhiemer's disease have been shown to have decreased presynaptic protein levels and impaired synaptic function in neurons. SNAP-25 can be used as a biomarker in the cerebral spinal fluid (CSF) of patients exhibiting different variations of Alzheimer's disease (prodromal Alzheimer's and overt Alzheimer's). Increased levels of SNAP-25 protein were observed in patients with Alzheimer's compared to control individuals. Additionally, the presence of truncated SNAP-25 protein can be seen in the CSF of some patients with this disease.[34] In five distinct regions of the brain, low levels of SNAP-25 can be seen in patients with Alzheimer's.[35]

Bipolar disorder

[edit]

A single nucleotide polymorphism in the SNAP-25 gene promoter has been shown to influence the expression levels of the SNAP-25b isoform in the prefrontal cortex. Increased levels of SNAP-25b have been shown to impair synaptic transmission and maturation which could lead to early-onset bipolar disorder (EOBD).The most abundant isoform of SNAP-25 is SNAP-25a during the early weeks of development in mice however in adulthood there is a change and the SNAP-25b isoform increases in the brain. This is shown to correlate with adolescent humans being increasingly diagnosed with EOBD during puberty.[36] It has been suggested that early-onset bipolar disorder is more closely linked to Schizophrenia than to Bipolar Disorder itself. The single nucleotide polymorphism of SNAP-25 (rs6039769) associated with EOBD has been shown to increase the risk of patients developing Schizophrenia.[19]

Botulism

[edit]

A genome wide association study pointed to the rs362584 polymorphism in the gene as possibly associated with the personality trait neuroticism.[37] Botulinum toxins A, C and E cleave SNAP-25,[38] leading to paralysis in clinically developed botulism.

Epilepsy

[edit]

Deletion of the SNAP-25b isoform has been shown to cause developmental abnormalities and seizures in mice. High levels of SNAP-25a and the protein syntaxin appear to be linked to seizures found in infantile-epilepsy. SNAP-25 knock-in mice have distinct phenotypic behavior similar to the fits and seizures of epileptic patients, as well as anxiety.[39]

Learning disabilities

[edit]

In the coloboma hyperactive mutant mouse model where SNAP-25 protein levels are reduced to 50% of the normal level, depolarized neurotransmitter release of dopamine and serotonin were reduced as well as glutamate release. The reduction in glutamate levels can lead to deficient memory and increased learning disabilities.[40] Certain polymorphisms of SNAP-25 (rs363043, rs353016, rs363039, rs363050) have been shown to affect the cognitive behavior, specifically the Intelligence Quotient (IQ)), of patients without pre-existing neurological diseases.[41]

Neonatal development

[edit]

SNAP-25 protein expression can be altered by sex hormone levels in neonatal rats. Male rats that received an antiestrogen drug showed a 30% decrease in SNAP-25 levels and females treated with estrogen or testosterone showed a 30% increase in SNAP-25 levels.[42] This suggests that synaptosomal proteins, such as SNAP-25, may have a dependence on neonatal hormone levels during brain development in rats. An additional study, showed that SNAP-25 levels in the hippocampus of the brain in neonatal mice were altered if the mother had been exposed to human influenza virus during pregnancy.[43]

Impact in other non-humans

[edit]

Loss is lethal to Drosophila, but can be fully substituted by overexpression of the related SNAP-24.[10]

Interactive pathway map

[edit]

Click on genes, proteins and metabolites below to link to respective articles.[§ 1]

[[File:
NicotineDopaminergic_WP1602go to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articleGo to articlego to articlego to articlego to articlego to articleGo to articleGo to articlego to articleGo to articleGo to articleGo to articlego to articleGo to articleGo to articleGo to articlego to articlego to articlego to articlego to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to article
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
NicotineDopaminergic_WP1602go to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articleGo to articlego to articlego to articlego to articlego to articleGo to articleGo to articlego to articleGo to articleGo to articleGo to articlego to articleGo to articleGo to articleGo to articlego to articlego to articlego to articlego to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to articlego to articleGo to articlego to articleGo to articleGo to articlego to article
|alt=Nicotine Activity on Dopaminergic Neurons edit]]
Nicotine Activity on Dopaminergic Neurons edit
  1. ^ The interactive pathway map can be edited at WikiPathways: "NicotineDopaminergic_WP1602".

Interactions

[edit]

SNAP-25 has been shown to interact with:

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

SNAP25

View on Grokipedia
from Grokipedia
SNAP-25 (synaptosomal-associated protein 25) is a presynaptic t-SNARE protein essential for the calcium-triggered exocytosis of synaptic vesicles and the regulated release of neurotransmitters in neurons.[1] Encoded by the SNAP25 gene on human chromosome 20p12.2, it consists of 16 exons and produces a 206-amino-acid protein with a molecular weight of approximately 25 kDa.[1] Unlike typical SNARE proteins with transmembrane domains, SNAP-25 anchors to the cytosolic face of the plasma membrane through palmitoylation of four cysteine residues in its central linker domain, allowing it to participate in membrane fusion without direct transmembrane insertion.[2] SNAP-25 functions primarily by forming a core SNARE complex with syntaxin-1 (another t-SNARE) and VAMP2/synaptobrevin (a v-SNARE on synaptic vesicles), which zippers together to bring vesicle and plasma membranes into close proximity, driving fusion and neurotransmitter release.[2] Its structure includes two SNARE motifs (SN1 and SN2) connected by a flexible linker domain of approximately 56 amino acids, which modulates fusion pore dynamics, secretion kinetics, and interactions with regulatory proteins.[3] The protein exists in two major isoforms, SNAP-25A and SNAP-25B, generated by alternative splicing of exon 5; SNAP-25A predominates during embryonic development, while SNAP-25B becomes the primary form in mature neurons, influencing synaptic transmission efficiency.[2] Expression of SNAP-25 is highly restricted to neural tissues, with the highest levels in the brain (RPKM ~418.5), particularly in presynaptic terminals of cortical, hippocampal, and cerebellar neurons, though lower postsynaptic expression has been detected.[1] Beyond its classical presynaptic role, emerging evidence indicates postsynaptic functions, including regulation of NMDA and kainate receptor trafficking, dendritic spine morphogenesis via interactions with p140Cap and PSD-95, and synaptic plasticity.[2] Dysfunction in SNAP-25 is implicated in various neurological and psychiatric disorders; for instance, mutations cause congenital myasthenic syndrome 18 (CMS18) and developmental epileptic encephalopathy 117 (DEE117), both characterized by impaired synaptic transmission. Recent studies (as of 2024) have further elucidated how DEE-associated variants alter SNARE complex stability.[1][4] Polymorphisms in SNAP25 are associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder (ADHD), and epilepsy, often through altered expression or complex formation that disrupts synaptic signaling.[2]

Gene and expression

Genomic organization

The SNAP25 gene is located on the short arm of human chromosome 20 at cytogenetic band p12.2, with genomic coordinates spanning from 10,218,830 to 10,307,418 (GRCh38 assembly), covering approximately 89 kb.[5][1] The orthologous Snap25 gene in mouse is situated on chromosome 2 (positions 136,555,373-136,624,348, GRCm39 assembly), spanning about 69 kb. The human SNAP25 gene consists of 9 exon units, including mutually exclusive exons 5a and 5b, and the canonical transcript (ENST00000254976.11) utilizes 8 exons, with alternative splicing primarily involving exons 5a and 5b that contribute to isoform diversity.[6] Exon boundaries are structured such that exons 1-4 and 6-8 encode regions flanking the variable exon 5, while specific exons align with sequences that translate into structural motifs essential for protein function, such as coiled-coil domains in exons 4 and 5.[5] This organization supports the generation of two major protein isoforms, SNAP25A and SNAP25B, through the inclusion of either exon 5a or 5b. SNAP25 exhibits strong evolutionary conservation across vertebrates, with sequence identity exceeding 99% between human and mouse orthologs, reflecting its critical role in conserved cellular processes.[7] Homologs are also present in invertebrates, including the Snap gene in Drosophila melanogaster, which spans over 120 kb with 8 exons and demonstrates functional similarity in synaptic vesicle trafficking.[8] This conservation underscores the ancient origins of the SNAP25 family, traceable to early metazoans.[9] A notable polymorphism in the SNAP25 gene is rs3746544 (T>G) located in the 3' untranslated region (3'-UTR), which influences mRNA stability and expression levels by altering binding sites for microRNAs such as miR-641.[10] The minor G allele has been shown to reduce SNAP25 transcript abundance in neuronal tissues.

Expression patterns and regulation

SNAP25 exhibits high expression in neuronal tissues, particularly within presynaptic terminals of the central and peripheral nervous systems, where it is enriched in synaptic vesicles and plasma membranes.[11] Lower levels of expression are observed in neuroendocrine cells and select non-neuronal tissues, such as pancreatic beta cells in the islets of Langerhans, supporting regulated exocytosis in these secretory systems.[12] According to expression data from the Human Protein Atlas and NCBI, SNAP25 shows restricted tissue specificity toward the brain, with an average RPKM of 418.5 in neural tissues compared to minimal detection elsewhere.[13][1] During development, SNAP25 expression is upregulated in conjunction with synaptogenesis, starting from low levels in embryonic brain and progressively increasing to peak in adulthood. This temporal pattern is evident across key brain regions, including the cerebral cortex and hippocampus, where the SNAP25B isoform predominates in mature neurons, reflecting enhanced synaptic maturation and plasticity.[14] Fetal expression data indicate presence in brain as early as 10-20 weeks gestation, with broader but lower detection in other organs like adrenal and heart.[1] The expression of SNAP25 is tightly regulated by core promoters and distal enhancers that drive neuron-specific transcription, with the repressor element 1-silencing transcription factor (REST/NRSF) playing a key role in silencing the gene in non-neuronal cells.[15] Epigenetic modifications, including histone acetylation at promoter regions and DNA methylation patterns, further modulate neuronal expression by maintaining an open chromatin state in brain tissues while repressing it elsewhere.[16] Alternative promoter usage contributes to the generation of tissue-specific transcripts, enabling differential isoform production that aligns with developmental and cellular contexts.[1]

Protein structure

Domains and motifs

The SNAP25 protein comprises 206 amino acids in its primary human isoform, exhibiting a modular architecture without a transmembrane domain that distinguishes it from other SNARE family members.[7] Central to its structure are two SNARE motifs, SN1 and SN2, which adopt alpha-helical conformations and contribute to the formation of parallel coiled-coil bundles in the SNARE complex.[17] These motifs enable SNAP25 to act as a Q-SNARE, with each containing a conserved glutamine residue in the characteristic Q-SNARE signature sequence that facilitates heterotetrameric assembly.[18] The N-terminal domain houses the SN1 motif, while the C-terminal domain contains the SN2 motif, connected by a flexible linker that imparts structural versatility. The cysteine-rich linker region, spanning approximately amino acids 85-140, includes key palmitoylation sites at Cys85, Cys88, Cys90, and Cys92, which support membrane anchoring through lipid modification.[19] Crystal structures of SNAP25 in complex with partner SNAREs, such as those deposited in the Protein Data Bank (e.g., PDB entry 1JTH), reveal alpha-helical bundles where the SN1 and SN2 helices from SNAP25 integrate into an elongated four-helix motif, underscoring the protein's role in stable complex formation.[20]

Isoforms and post-translational modifications

SNAP25 is expressed as two primary isoforms, SNAP-25A and SNAP-25B, arising from alternative splicing of mutually exclusive exons 5A and 5B within the SNAP25 gene. These isoforms share identical sequences except for nine amino acid differences in a central linker region between the two SNARE motifs.[21][22] SNAP-25A predominates during embryonic and early postnatal brain development, supporting initial synaptogenesis, whereas SNAP-25B expression increases postnatally and becomes the major isoform in mature neurons, particularly in the hippocampus and cortex.[23][24] Post-translational modifications significantly influence SNAP25 localization, stability, and activity. Palmitoylation at four cysteine residues (Cys85, Cys88, Cys90, and Cys92) in the cysteine-rich domain anchors SNAP25 to the plasma membrane, enabling its integration into synaptic vesicle fusion machinery; dynamic depalmitoylation and repalmitoylation by DHHC enzymes regulate this process.[25][26] Phosphorylation at serine 187 by protein kinase C (PKC) enhances SNAP25 function in exocytosis, promoting SNARE complex assembly and synaptic facilitation without altering membrane targeting.[27][28] Ubiquitination modulates SNAP25 stability, as activity-dependent polyubiquitination targets it for proteasomal degradation, preventing accumulation and maintaining synaptic homeostasis.[29][30] The molecular chaperone Hsc70, often in complex with cysteine string protein α (CSPα), facilitates SNAP25 folding and prevents its aggregation into non-functional states, a process critical for preserving synaptic proteostasis.[31][32] Compared to SNAP-25A, the SNAP-25B isoform supports more efficient synaptic vesicle fusion, exhibiting two- to three-fold greater efficacy in driving neurotransmitter release in reconstituted systems and neuronal models.[33][34]

Biological function

Role in SNARE complex and exocytosis

SNAP25 functions as a principal t-SNARE protein anchored to the presynaptic plasma membrane, where it heterodimerizes with syntaxin-1 to create a binary acceptor complex for the v-SNARE VAMP2 (also known as synaptobrevin-2) on synaptic vesicles, thereby mediating Ca²⁺-dependent neurotransmitter release through exocytosis.[35] This ternary SNARE assembly forms a stable four-helix bundle that zippers from N- to C-termini, drawing the vesicle and plasma membranes into close apposition to overcome the energy barrier for fusion.[35] Unlike syntaxin-1 and VAMP2, which each contribute a single α-helix and possess transmembrane domains, SNAP25 provides two parallel SNARE motifs linked by a flexible linker domain containing cysteine residues for palmitoylation, allowing soluble assembly and membrane attachment via palmitoylation rather than a transmembrane anchor.[35] The formation of this SNARE complex is critical for synaptic vesicle priming at the active zone, positioning vesicles in a release-ready state competent for rapid fusion upon calcium influx, and its disassembly post-fusion enables recycling.[36] Genetic ablation of SNAP25 in mice results in perinatal lethality attributable to profound defects in evoked synaptic transmission, with near-complete loss of Ca²⁺-triggered release while spontaneous miniature events persist at reduced levels, underscoring its indispensable role in regulated exocytosis.[37] SNAP25 briefly interacts with syntaxin-1 and VAMP2 during complex assembly to drive these processes.[35] Proteomic quantification reveals SNAP25 as one of the most abundant presynaptic proteins, with approximately 100–200 molecules localized per active zone to support high-fidelity release, and the SNARE complex enables fusion kinetics on the sub-millisecond timescale synchronized to calcium channel opening.[38][39] This molecular architecture ensures efficient, synchronous neurotransmitter discharge essential for neural signaling.[39]

Regulatory mechanisms and emerging roles

The activity of SNAP25 is tightly regulated post-fusion by the ATPase NSF in complex with α-SNAP, which disassembles SNARE complexes to recycle components for subsequent rounds of exocytosis.[40] NSF binds to the SNARE complex via α-SNAP, and ATP hydrolysis drives the mechanical separation of SNAP25, syntaxin-1, and VAMP2, preventing their persistent association and enabling SNARE reuse.[41] This disassembly is essential for maintaining efficient synaptic transmission, as persistent SNARE complexes would otherwise inhibit further vesicle priming.[42] Prior to fusion, SNAP25 function is modulated by accessory proteins such as Munc18-1 and complexin, which clamp SNARE assembly to ensure calcium-triggered synchrony. Munc18-1 binds to the syntaxin-1/SNAP25 binary complex, stabilizing it in a pre-fusion state and preventing premature full zippering until Munc13-1 facilitates progression.[43] Complexin further clamps this partially assembled SNARE complex by laterally binding to it, inhibiting spontaneous fusion while sensitizing the system to synaptotagmin-1 activation upon calcium influx.[44] Recent studies have highlighted chaperone systems involving Hsc70 that maintain SNAP25 solubility and prevent aggregation, particularly under synaptic stress. The Hsc70 chaperone, in cooperation with CSPα, binds monomeric SNAP25 to keep it in an assembly-competent conformation, delaying its aggregation and ensuring availability for SNARE complex formation.[45] This mechanism is critical for synaptic integrity, as SNAP25 aggregation disrupts exocytosis and contributes to neurodegenerative pathologies.[46] Emerging evidence points to postsynaptic roles for SNAP25 beyond presynaptic exocytosis, including regulation of receptor trafficking and dendritic spine morphology. In hippocampal neurons, SNAP25 interacts with p140Cap to control AMPA receptor endocytosis and stabilize spine density, influencing synaptic plasticity.[47] Reduced SNAP25 levels increase PSD-95 mobility and impair spine morphogenesis, underscoring its contribution to postsynaptic architecture.[2] In non-neuronal contexts, SNAP25 supports insulin secretion from pancreatic β-cells by forming SNARE complexes that mediate glucose-stimulated granule exocytosis. SNAP25 isoforms, particularly SNAP-25b, enhance calcium-dependent insulin release, with deficiencies leading to altered granule dynamics and increased basal secretion.[48] Botulinum neurotoxin cleavage of SNAP25 confirms its necessity, as it potently inhibits insulin exocytosis similar to neurotransmitter release.[49] Structural studies from 2025 provide new insights into NSF-mediated remodeling of SNAP25-syntaxin complexes, revealing how NSF/α-SNAP disassembles non-fusogenic binary complexes to liberate syntaxin for Munc18/Munc13 action. Cryo-EM structures show NSF engaging a 2:1 syntaxin-SNAP25 complex, inducing conformational changes that promote SNARE recycling and quality control at the active zone.[41] These findings elucidate how such remodeling ensures rapid SNARE turnover essential for high-fidelity synaptic transmission.[50]

Clinical significance in humans

Developmental and epileptic encephalopathies

Mutations in the SNAP25 gene are associated with developmental and epileptic encephalopathy 117 (DEE117; OMIM 616330), an autosomal dominant disorder primarily caused by de novo heterozygous variants that disrupt the protein's role in synaptic vesicle exocytosis. Deleterious variants, such as p.Val48Phe (V48F), p.Asp166Tyr (D166Y), and p.Ile67Asn (I67N), impair SNARE complex stability by altering key binding interfaces, including those with synaptotagmin-1, leading to defective neurotransmitter release.[4] These mutations are recurrent in affected individuals and have been identified through trio-based exome sequencing in cohorts of patients with early-onset epilepsy.[51] Clinically, SNAP25-related DEE117 manifests with severe neurological features, including infantile spasms in approximately 22% of cases, often accompanied by hypsarrhythmia on electroencephalography (EEG). Onset of seizures typically occurs within the first year of life, with a median age of 12 months, and is frequently refractory to antiepileptic drugs. Affected individuals exhibit profound intellectual disability (universal in reported cases), hypotonia, global developmental delay, and autism spectrum traits in about 17% of patients; additional features may include ataxia (33%), spasticity (19%), and movement disorders.[52][53] Brain imaging often reveals cerebral visual impairment or mild atrophy, though findings are variable.[51] The underlying pathophysiology involves reduced evoked neurotransmitter release due to SNARE complex dysfunction, resulting in neuronal hyperexcitability and impaired synaptic transmission. Recent studies using molecular dynamics simulations have shown that these variants alter the energy landscape of synaptic exocytosis; for instance, V48F and D166Y lower the fusion energy barrier, promoting spontaneous release while diminishing the readily releasable pool, whereas I67N acts dominantly negative to increase the barrier and suppress release overall.[4] This dual loss- and gain-of-function mechanism contributes to the epileptic phenotype and developmental arrest. Diagnosis relies on whole-exome or targeted sequencing to identify SNAP25 variants, supported by EEG and clinical evaluation. Currently, no targeted therapies exist; management is supportive, involving antiepileptic drugs (e.g., valproic acid or clonazepam with partial response in some), ketogenic diet, or corticosteroids for spasms, though outcomes remain poor.[53][52]

Neurodevelopmental and psychiatric disorders

Single nucleotide polymorphisms (SNPs) in the SNAP25 gene have been implicated in the risk for attention-deficit/hyperactivity disorder (ADHD), with the rs1051312 variant showing consistent associations across studies. This SNP, located in the 3' untranslated region, influences SNAP25 expression and is linked to altered dopamine release in prefrontal cortical regions critical for attention and executive function. Meta-analyses of multiple cohorts indicate that carriers of the minor allele exhibit modestly increased ADHD risk, with odds ratios ranging from 1.14 to 1.19, highlighting its contribution as a common genetic factor rather than a deterministic one.[54][55][56] In schizophrenia, the rs363039 SNP has been associated with altered cortical SNAP25 expression, potentially disrupting synaptic transmission in prefrontal areas involved in cognition and perception. Reduced SNAP25 levels in postmortem brain tissue from schizophrenia patients correlate with this variant, suggesting a role in synaptic hypofunction that exacerbates psychotic symptoms. For bipolar disorder, the promoter region SNP rs6039769 (also referred to as rs603976 in some datasets) is linked to early-onset cases, where the risk allele promotes higher SNAP25 expression in the prefrontal cortex, possibly leading to dysregulated neurotransmitter release during manic episodes. These associations underscore SNAP25's involvement in psychiatric disorders through subtle gene expression changes.[57][58][59] The underlying mechanisms involve partial haploinsufficiency from these common variants, resulting in mild synaptic deficits that accumulate to influence neurodevelopmental trajectories. Unlike rare monogenic mutations, these polymorphisms do not cause disorders in isolation but interact within polygenic networks to modulate synaptic vesicle trafficking and neurotransmitter homeostasis. No evidence supports monogenic causality for ADHD, schizophrenia, or learning disabilities via SNAP25 alone.[60][61]

Neurodegenerative diseases

SNAP25 plays a critical role in synaptic dysfunction underlying Alzheimer's disease (AD), where reduced levels in brain tissue and amyloid plaques serve as indicators of progressive synaptic loss. As a key component of the SNARE complex, diminished SNAP25 expression correlates with the severity of cognitive decline, with 2023 studies demonstrating its utility as a cerebrospinal fluid (CSF) biomarker for monitoring synapse degeneration in AD patients. For instance, longitudinal analyses have shown that lower SNAP25 concentrations in synaptic fractions precede overt neuronal damage, highlighting its involvement in early pathological cascades.[62][63] In AD pathophysiology, synaptic degeneration occurs prior to widespread neuronal loss, disrupting neurotransmitter release and contributing to memory impairment. SNAP25 undergoes cleavage by caspases during apoptotic processes in affected neurons, exacerbating exocytosis deficits and amplifying synaptic vulnerability. This proteolytic modification, activated by amyloid-beta toxicity, further impairs SNARE complex assembly and is observed in preclinical models of AD.[64][65] In Parkinson's disease (PD), alpha-synuclein aggregates interfere with SNAP25 palmitoylation, a post-translational modification essential for its membrane anchoring and function, thereby reducing vesicular exocytosis and dopaminergic transmission. A 2025 review underscores this mechanism as a potential early therapeutic target, where restoring palmitoylation could mitigate synaptic pathology and slow disease progression. Clinically, CSF SNAP25 assays aid in diagnosing AD and PD, with significant level reductions—often 20-50%—evident in prodromal stages, enabling earlier intervention before substantial cognitive deficits emerge. These assays distinguish neurodegenerative synaptic loss from other conditions, though overlaps with psychiatric disorders like schizophrenia warrant cautious interpretation.[66][67][63]

Toxin-mediated pathologies

Botulinum neurotoxins (BoNTs) serotypes A and E specifically target SNAP25, a key component of the SNARE complex essential for synaptic vesicle exocytosis. BoNT/A cleaves SNAP25 at the peptide bond between glutamine 197 and arginine 198 (Q197-R198), while BoNT/E cleaves it between arginine 180 and isoleucine 181 (R180-I181).[68][69] These cleavages truncate the C-terminal region of SNAP25, preventing the formation of functional SNARE complexes and thereby inhibiting neurotransmitter release at neuromuscular junctions.[70] In clinical botulism, primarily caused by ingestion or inhalation of BoNTs produced by Clostridium botulinum, the toxin's action on SNAP25 leads to flaccid paralysis through blockade of acetylcholine release from presynaptic terminals. Symptoms typically manifest as descending muscle weakness, starting with cranial nerves and progressing to respiratory and limb muscles, potentially resulting in respiratory failure if untreated.[71] Infant botulism, the most common form in young children, arises from the germination of C. botulinum spores in the immature gut, where the bacteria produce toxin in situ, leading to similar paralytic effects.[72] Therapeutically, purified BoNT/A (onabotulinumtoxinA) is widely used to treat conditions involving excessive muscle activity, such as cervical dystonia and chronic migraine, by locally injecting the toxin to induce targeted SNAP25 cleavage and temporary denervation. The FDA has approved BoNT/A for cervical dystonia in adults, where it reduces abnormal head positioning and neck pain. For chronic migraine, prophylactic injections decrease headache frequency and severity, with effects mediated by SNAP25 truncation in peripheral sensory neurons. The duration of therapeutic paralysis from BoNT/A typically lasts 3-6 months, attributed to the persistence of the cleaved SNAP25 fragment and gradual resynthesis of intact protein.[73][74] Recent studies highlight that BoNT/A cleavage of SNAP25 is often partial rather than complete, allowing residual SNARE function that contributes to gradual neuromuscular recovery without full resynthesis in some neuronal compartments. This acute, toxin-induced synaptic blockade differs mechanistically from endogenous protein dysregulation, with no pathological overlap in clinical presentation or progression.[75]

Studies in model organisms

Invertebrate models

Studies in invertebrate model organisms, particularly Drosophila melanogaster and yeast, have provided key insights into the conserved roles of SNAP25 homologs in membrane fusion processes. In Drosophila, the SNAP25 ortholog, encoded by the Snap25 gene, is crucial for synaptic transmission at the neuromuscular junction. Null mutants of Snap25 are viable through the larval stage but fail to eclose as adults due to impaired neurotransmitter release, with compensation by the related protein SNAP-24 during early development. A temperature-sensitive allele, SNAP-25^{ts}, induces reversible paralysis at restrictive temperatures (29°C), demonstrating the protein's essential role in evoked synaptic vesicle exocytosis without affecting spontaneous release under certain conditions.[76] Rescue experiments further highlight the functional conservation of SNAP25. Transgenic expression of wild-type Drosophila SNAP25 fully restores viability and synaptic function in null or ts mutants, confirming its specificity in SNARE complex assembly. Due to approximately 61% amino acid identity between Drosophila SNAP25 and human SNAP25,[77] these findings underscore SNAP25's role in docking and priming synaptic vesicles for Ca^{2+}-triggered fusion, a mechanism conserved from invertebrates to humans. Evolutionary perspectives are deepened by studies in unicellular eukaryotes like Saccharomyces cerevisiae, where the SNAP25 homolog Sec9p participates in a SNARE complex mediating exocytosis of post-Golgi secretory vesicles to the plasma membrane. Unlike metazoan SNAP25, which is neuron-specific and membrane-anchored via palmitoylation, Sec9p lacks such targeting and supports general secretory fusion without neuronal specialization. This highlights SNAP25's ancestral role in intracellular trafficking, evolving toward specialized synaptic functions in higher organisms.[78] Recent investigations in 2025 have elucidated structural dynamics of SNAP25-containing complexes in cellular models, revealing NSF-mediated remodeling that parallels mechanisms in Drosophila synapses. NSF, an AAA+ ATPase, disassembles non-fusogenic binary syntaxin-SNAP25 complexes, liberating syntaxin for productive SNARE assembly and vesicle priming. In fly neuromuscular junctions, this process prevents off-pathway aggregates, ensuring efficient neurotransmission and mirroring NSF's quality-control function observed in mammalian synapses via cryo-EM structures of SNARE supercomplexes.[41]

Vertebrate and mammalian models

Homozygous knockout of SNAP25 in mice results in perinatal lethality, with embryos viable until late gestation but failing to survive postnatally due to severe impairments in synaptic vesicle exocytosis and evoked neurotransmitter release, highlighting SNAP25's essential role in vesicle trafficking.[79] Heterozygous SNAP25 mice exhibit increased susceptibility to kainate-induced seizures, spontaneous epileptiform activity in hippocampal slices, and cognitive deficits that are ameliorated by antiepileptic drugs like valproate and carbamazepine, underscoring the protein's involvement in seizure generation and synaptic function.[80] Brain-specific conditional knockout models further demonstrate synaptic deficits, elevated extracellular glutamate levels, contributing to behavioral abnormalities reminiscent of neuropsychiatric disorders.[81] Isoform-specific models reveal differential roles of SNAP25 variants in mammalian physiology. Mice expressing only the SNAP25A isoform (achieved via SNAP25B knockout with SNAP25A knock-in) are viable but display spontaneous seizures, hyperactivity, anxiety-like behaviors in elevated plus maze tests, and learning impairments in fear conditioning tasks, linking SNAP25 dysregulation to epilepsy and attention-deficit/hyperactivity disorder (ADHD) models.[82] These phenotypes arise from altered synaptic transmission and vesicle priming, with SNAP25B normally dominating in adult neurons for efficient exocytosis, while SNAP25A suffices developmentally but leads to deficits when persistently expressed.[83] SNAP25 heterozygous knockout mice also serve as ADHD models, showing delayed motor development, hyperactivity in open field tests, and attention deficits, supporting genetic contributions of SNAP25 to neurodevelopmental disorders.[84] In zebrafish, morpholino-mediated knockdown of SNAP25 disrupts synaptic transmission, impairs motor neuron development, and induces movement disorders characterized by reduced locomotion and uncoordinated swimming, phenotypes that mimic aspects of epileptic seizures and facilitate high-throughput drug screening for neurodevelopmental therapies.[85][86] These models leverage zebrafish's optical transparency and rapid development to assess antiepileptic compounds, such as those targeting SNARE complex function, providing insights into SNAP25's conserved role in vertebrate synaptic physiology. Recent CRISPR/Cas9-engineered models have advanced understanding of SNAP25-related developmental and epileptic encephalopathies (DEE). Patient-derived mutations like I67N, introduced via CRISPR in human induced pluripotent stem cell (iPSC)-derived neurons, recapitulate synaptic dysfunction and hyperexcitability, offering platforms to test therapeutic responses and model human encephalopathies in mammalian cellular contexts.[87] These approaches complement traditional knockouts by enabling precise variant-specific studies, revealing altered SNARE complex assembly and spontaneous release as key mechanisms in DEE pathogenesis.[4]

Protein interactions

Key binding partners

SNAP25, a key Q-SNARE protein, primarily interacts with other SNARE family members to facilitate synaptic vesicle fusion. Its core binding partners include syntaxin-1A and syntaxin-1B, which are plasma membrane Qa-SNAREs that bind SNAP25 through their respective SNARE motifs to form a stable binary complex on the presynaptic membrane. This interaction has been characterized with high affinity, exhibiting a dissociation constant (Kd) of approximately 126 nM, as determined by quantitative binding assays on lipid bilayers.[88] Another essential partner is VAMP2 (vesicle-associated membrane protein 2), an R-SNARE anchored to the synaptic vesicle membrane, which engages the syntaxin-1/SNAP25 acceptor complex to form the trans-SNARE complex that drives membrane fusion. The assembly of this ternary SNARE complex proceeds with stepwise zippering of SNARE motifs, resulting in overall binding affinities in the low nanomolar range, supported by co-immunoprecipitation (co-IP) studies confirming stable interactions in neuronal extracts.[89][90] Among accessory proteins, Munc18-1 acts as a chaperone for syntaxin-1, indirectly influencing SNAP25 incorporation into the SNARE complex by stabilizing the closed conformation of syntaxin-1 prior to SNAP25 binding, as evidenced by co-IP experiments showing enhanced complex formation in the presence of Munc18-1. Complexin-1 and complexin-2 bind to the partially assembled SNARE complex involving SNAP25, functioning to clamp the complex and prevent premature fusion until calcium influx, with interactions verified through co-IP and binding assays in synaptic preparations.[91][92] Synaptotagmin-1, the primary calcium sensor for exocytosis, directly docks to the syntaxin-1/SNAP25 heterodimer via its C2 domains, promoting calcium-triggered SNARE complex completion, as demonstrated by liposome docking assays and co-IP in neuronal lysates. In contrast, SNAP-47, a related Qbc-SNARE with sequence homology to SNAP25, can form SNARE complexes with syntaxin-1 and VAMP2 in vitro but does not significantly interact with or substitute for SNAP25 in neuronal contexts, based on rescue experiments in SNAP25-deficient neurons showing minimal functional overlap.[93] These interactions have been extensively mapped using techniques such as yeast two-hybrid screening for initial partner identification and co-IP for validation in native systems, highlighting SNAP25's central role in the presynaptic interactome.[94][95]

Functional complexes and pathways

SNAP25 serves as a key t-SNARE protein in the formation of the core SNARE complex, which drives synaptic vesicle fusion with the plasma membrane during neurotransmitter release. It assembles with plasma membrane-anchored syntaxin-1 to form a stable binary t-SNARE complex, acting as an acceptor template for the v-SNARE synaptobrevin-2 (VAMP2) from the vesicle membrane. This ternary complex creates a four-helix bundle, where sequential N- to C-terminal zippering of VAMP2 generates approximately 85 k_BT of free energy to overcome the fusion barrier, with distinct kinetic steps: rapid N-terminal docking (~2×10^6 M^{-1}s^{-1}), a moderate middle-domain barrier (~5 k_BT), and higher energy costs for the C-terminal domain (~22 k_BT) and linker domain (~8 k_BT).[96][97] Assembly pathways for the SNARE complex involving SNAP25 are tightly regulated by accessory proteins to ensure precise timing in exocytosis. In the canonical t-SNARE pathway, the syntaxin-1/SNAP25 binary complex unfolds with ~17 k_BT energy, priming it for VAMP2 integration. An alternative Munc18-1-dependent pathway involves a preformed syntaxin-1/VAMP2 template on Munc18-1, where SNAP25 binds at ~5×10^5 M^{-1}s^{-1} and displaces Munc18-1 to complete the complex. Munc13-1 chaperones this process by recruiting SNAP25, opening closed syntaxin-1 conformers, and stabilizing intermediates, while complexin-1 clamps the partially zipped complex to prevent premature fusion until Ca^{2+}-synaptotagmin activation triggers full zippering. These pathways ensure SNAP25's role in Ca^{2+}-triggered, stimulus-evoked release at synapses.[98][99][100] Beyond exocytosis, SNAP25 participates in additional functional complexes modulating synaptic transmission. It interacts directly with voltage-gated calcium channels (e.g., N-type, P/Q-type, and L-type), forming complexes that negatively regulate Ca^{2+} influx to fine-tune presynaptic excitability.[101] In postsynaptic compartments, SNAP25 influences receptor trafficking pathways; phosphorylation at Ser187 by protein kinase C promotes its association with NMDA receptors, enhancing their surface delivery and synaptic plasticity.[102] Additionally, SNAP25 binds intersectin in endocytic complexes, supporting clathrin-mediated retrieval of synaptic vesicles and receptors like kainate GluK5 subunits via interactions with PICK1.[103][104] These diverse roles highlight SNAP25's integration into broader membrane trafficking and signaling pathways at synapses.

References

  1. SNAP25 synaptosome associated protein 25 [ (human)] - NCBI
  2. SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic ...
  3. Roles for the SNAP25 linker domain in the fusion pore and a ...
  4. 600322 - SYNAPTOSOMAL-ASSOCIATED PROTEIN, 25-KD; SNAP25
  5. https://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000132639;t=ENST00000254976
  6. SNAP25 - Synaptosomal-associated protein 25 | UniProtKB - UniProt
  7. Complex gene organization of synaptic protein SNAP-25 in ...
  8. Evolutionary conservation of synaptosome-associated protein 25 ...
  9. DNA Variation in the SNAP25 Gene Confers Risk to ADHD and Is ...
  10. Distribution and expression of SNAP-25 immunoreactivity in rat ...
  11. SNAP-25 is expressed in islets of Langerhans and is involved in ...
  12. SNAP25 protein expression summary - The Human Protein Atlas
  13. Regional and developmental brain expression patterns of SNAP25 ...
  14. Genome-wide analysis of repressor element 1 silencing ... - NIH
  15. article Differential Promoter Methylation and Histone Modification ...
  16. SNAP-25 IS ALSO AN IRON-SULFUR PROTEIN - PubMed Central
  17. The SNAP-25 Protein Family - ScienceDirect.com
  18. Characterization of the Palmitoylation Domain of SNAP-25 - PubMed
  19. 1JTH: Crystal structure and biophysical properties of a complex ...
  20. Human cDNA clones encoding two different isoforms of the nerve ...
  21. SNAP-25 isoforms differentially regulate synaptic transmission and ...
  22. Developmental and plasticity-related differential expression of two ...
  23. SNAP-25a and SNAP-25b Differently Mediate Interactions ... - PubMed
  24. Differential palmitoylation regulates intracellular patterning of SNAP25
  25. SNAP-25 Is Targeted to the Plasma Membrane through a Novel ...
  26. SNAP-25 phosphorylation at Ser187 regulates synaptic facilitation ...
  27. Protein kinase C-dependent phosphorylation of synaptosome ...
  28. Intra-axonal Synthesis of SNAP25 Is Required for the Formation of ...
  29. Targeting botulinum neurotoxin persistence by the ubiquitin ...
  30. The Hsc70 system maintains the synaptic SNARE protein SNAP-25 ...
  31. The Role of Co-chaperones in Synaptic Proteostasis and ... - PubMed
  32. Differential Control of the Releasable Vesicle Pools by SNAP-25 ...
  33. SNAP-25a and SNAP-25b differently mediate interactions with ...
  34. Crystal structure of a SNARE complex involved in synaptic ... - PubMed
  35. A dominant mutation in Snap25 causes impaired vesicle trafficking ...
  36. Science | AAAS
  37. The SNARE protein SNAP-25 is linked to fast calcium triggering of ...
  38. Stimulation of NSF ATPase Activity by α-SNAP Is Required for ... - NIH
  39. Structural remodeling of target-SNARE protein complexes by NSF ...
  40. NSF-mediated disassembly of on- and off-pathway SNARE ... - eLife
  41. Munc18-1 binding to the neuronal SNARE complex controls ... - NIH
  42. SNAP25 disease mutations change the energy landscape for ... - eLife
  43. The Hsc70 system maintains the synaptic SNARE protein SNAP-25 ...
  44. The Hsc70 system maintains the synaptic SNARE protein SNAP-25 ...
  45. SNAP-25 regulates spine formation through postsynaptic binding to ...
  46. SNAP-25b-deficiency increases insulin secretion and changes ...
  47. SNAP-25 is expressed in islets of Langerhans and ... - PubMed - NIH
  48. Structural remodeling of target-SNARE protein complexes by NSF ...
  49. SNAP25 disease mutations change the energy landscape for ... - eLife
  50. De novo variants in SNAP25 cause an early-onset developmental ...
  51. 616330 - DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY ...
  52. Synaptopathies in Developmental and Epileptic Encephalopathies
  53. The Association of SNAP25 Gene Polymorphisms in Attention Deficit ...
  54. Association of SNAP-25 Gene Ddel and Mnll Polymorphisms ... - NIH
  55. 2.4 - Clinical Psychopharmacology and Neuroscience
  56. Association between SNAP-25 gene polymorphisms and cognition ...
  57. A Multilevel Functional Study of a SNAP25 At-Risk Variant for ...
  58. A SNAP25 promoter variant is associated with early-onset bipolar ...
  59. Mutation in SNAP25 causes epilepsy & intellectual disability
  60. De novo variants in SNAP25 cause an early-onset developmental ...
  61. Polygenic scores for autism are associated with reduced neurite ...
  62. SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic ...
  63. Genetics of attention deficit hyperactivity disorder - Nature
  64. SNAP25 is a potential target for early stage Alzheimer's disease and ...
  65. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP ...
  66. Knock-in models related to Alzheimer's disease: synaptic ...
  67. An Atypical, Staged Cell Death Pathway Induced by Depletion of ...
  68. Protein regulatory network mediated by palmitoylation modifications ...
  69. Upregulation of cellular palmitoylation mitigates α-synuclein ...
  70. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.
  71. Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin ...
  72. Article Botulinum Toxins A and E Inflict Dynamic Destabilization on t ...
  73. Botulism - StatPearls - NCBI Bookshelf - NIH
  74. Infantile Botulism - StatPearls - NCBI Bookshelf - NIH
  75. [PDF] BOTOX (onabotulinumtoxinA) Label - accessdata.fda.gov
  76. Botulinum Toxin in the Treatment of Headache - PMC - NIH
  77. Persistence of Botulinum Neurotoxin A Subtypes 1-5 in Primary Rat ...
  78. A Drosophila SNAP-25 null mutant reveals context-dependent ... - NIH
  79. Evolutionary Conservation of Synaptosome-Associated Protein 25 ...
  80. Epileptiform Activity and Cognitive Deficits in SNAP-25+/− Mice are ...
  81. Brain-Specific SNAP-25 Deletion Leads to Elevated Extracellular ...
  82. Genetic disorders of neurotransmitter release machinery - Frontiers
  83. Snap25 heterozygous knockout mice as a model for attention deficit ...
  84. miR-153 Regulates SNAP-25, Synaptic Transmission, and Neuronal ...
  85. Seizing the moment: Zebrafish epilepsy models - ScienceDirect.com
  86. SNAP25 variant I67N: synaptic phenotypes, drug response and ...
  87. Accessory proteins stabilize the acceptor complex for synaptobrevin ...
  88. Different regions of synaptic vesicle membrane regulate VAMP2 ...
  89. Munc18-1 is crucial to overcome the inhibition of synaptic vesicle ...
  90. Interactions Between SNAP-25 and Synaptotagmin-1 Are Involved ...
  91. SNAP-25 gene family members differentially support secretory ...
  92. CytLEK1 Is a Regulator of Plasma Membrane Recycling through Its ...
  93. Spring, a Novel RING Finger Protein That Regulates Synaptic ...
  94. https://doi.org/10.7554/eLife.41771
  95. Energetics, kinetics, and pathways of SNARE assembly in ...
  96. https://doi.org/10.1002/1873-3468.14006
  97. https://doi.org/10.1038/nature25481
  98. https://doi.org/10.1126/science.1224492
  99. https://doi.org/10.1074/jbc.M110.145813
  100. https://doi.org/10.1038/ncomms3136
User Avatar
No comments yet.